1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Pixium's IRIS II CE Mark Stokes Retinal Implant Rivalry

 
• By Tina Tan

Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.

Visual perception

Pixium Vision has CE-marked its second-generation bionic vision system, IRIS II, and plans to commercialize it in Europe at the end of this year. It is the second device of its kind to enter the market, breaking the monopoly held by Second Sight Medical Products Inc.'s for the past five years.

IRIS II is approved for people with vision loss from outer retinal degeneration. Similar to Second Sight's Argus II, which was CE marked in 2011, IRIS II includes a camera...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.